ELND005

DRUG4 trials

Sponsors

OPKO Health, Inc.

Conditions

Alzheimer DiseaseAlzheimer's DiseaseBipolar 1 DisorderDown Syndrome

Phase 2

ELND005 in Patients With Mild to Moderate Alzheimer's Disease

CompletedNCT00568776

OPKO Health, Inc.Alzheimer Disease

Start: 2007-12-31End: 2010-05-31Updated: 2019-11-01

Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

TerminatedNCT01674010

OPKO Health, Inc.Bipolar 1 Disorder

Start: 2012-08-31End: 2014-06-30Updated: 2019-10-21

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

CompletedNCT01735630

OPKO Health, Inc.Alzheimer's Disease

Start: 2012-11-30End: 2015-05-31Updated: 2019-10-21

A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia

CompletedNCT01791725

OPKO Health, Inc.Down Syndrome

Start: 2013-09-30End: 2014-06-30Updated: 2019-11-04

Related Papers

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia.

2017-01-0132 citations

P1‐392: DRUG DEVELOPMENT FOR AGITATION AND AGGRESSION IN ALZHEIMER'S DISEASE (AD): STUDY DESIGN AND OUTCOME MEASURES IN PHASE 2 STUDY OF SCYLLO‐INOSITOL (ELND005 STUDY AG201)

Alzheimer s & Dementia2014-07-011 citations

P4‐169: SELECTION OF DOSING REGIMEN FOR ELND005 (SCYLLO‐INOSITOL) STUDY IN PATIENTS WITH AGITATION AND AGGRESSION OF ALZHEIMER'S DISEASE (AD)

Alzheimer s & Dementia2014-07-01